

High-sensitivity COVID-19 group testing by digital PCR

Authors: Alexandra Martin (1), Alexandre Storto (2,3), Barbara André (1), Allison Mallory (1), Rémi Dangla (1), Benoit Visseaux (2,3), Olivier Gossner (4)

((1) Stilla Technologies, Villejuif, France, (2) Université de Paris, Assistance Publique – Hôpitaux de Paris, Service de virologie, Hôpital Bichat, Paris, France (3) UMR 1137-IAME, DeSCID: Decision Sciences in Infectious Diseases control and care, INSERM, Université de Paris, Paris, France, (4) CREST, Ecole Polytechnique, Palaiseau, France)

Comments: 17 pages, 6 figures

Abstract

Background: Worldwide demand for SARS-CoV-2 RT-PCR testing is increasing as more countries are impacted by COVID-19 and as testing remains central to contain the spread of the disease, both in countries where the disease is emerging and in countries that are past the first wave but exposed to re-emergence. Group testing has been proposed as a solution to expand testing capabilities but sensitivity concerns have limited its impact on the management of the pandemic. Digital PCR (RT-dPCR) has been shown to be more sensitive than RT-PCR and could help in this context.

Methods: We implemented RT-dPCR based COVID-19 group testing on commercially available system and assay (Naica™ System from Stilla Technologies) and investigated the sensitivity of the method in real life conditions of a university hospital in Paris, France, in May 2020. We tested the protocol in a direct comparison with reference RT-PCR testing on 448 samples split into groups of 3 sizes for RT-dPCR analysis: 56 groups of 8 samples, 28 groups of 16 samples and 14 groups of 32 samples.

Results: Individual RT-PCR testing identified 25 positive samples. Using groups of 8, testing by RT-dPCR identified 23 groups as positive, corresponding to 26 true positive samples including 2 samples not initially detected by individual RT-PCR but confirmed positive by further RT-PCR and RT-dPCR investigation. For groups of 16, 15 groups tested positive, corresponding to 25 true positive samples identified. 100% concordance is found for groups of 32 but with limited data points.

Conclusions: Our proposed approach of group testing by digital PCR is shown to have a similar to better diagnostic sensitivity compared to individual RT-PCR testing for group sizes of up to 16 samples. This approach reduces the quantity of reagent needed by up to 80% while reducing costs and increasing capabilities of testing by up to 10-fold.

Key words

SARS-CoV-2, COVID-19, group testing, sample pooling, RT-PCR, digital PCR

Introduction

As the first wave of the COVID-19 is fading in most countries of the Northern hemisphere, many of them have started implementing extensive monitoring policies to prevent the apparition of new clusters potentially leading to a second wave. These policies all require important testing capabilities, as was exemplified in Wuhan where all 11 Million citizens were recently tested in 10 days during May 2020. In some Southern countries, the amount of new cases is still increasing and wide population testing cannot be achieved everywhere. Thus, scaling up and maintaining large testing capacities worldwide remains a challenge, with limited reagent production and scarcity of testing equipment likely to remain limitations.

Group testing or pooling, first suggested by Dorfman in 1943, is a protocol through which individual samples are combined together before running the test(1). The advantage of the method is an overall saving in the number of tests required to screen a given population (2), and thereby an increase in testing capabilities for fixed reagent and instrumentation availability. Savings depend on key parameters such as the disease prevalence and the group size. Group testing protocols using real-time reverse-transcriptase PCR (RT-PCR) have been evaluated and implemented for Covid-19 screening around the world in several experiments using RT-PCR detection techniques, notably in Israel, Germany, California, Nebraska, NY State, and Italy (3–9).

Although these studies show that positive individuals can be detected in pooled samples, the number of amplification cycles needed to detect (Ct value) those is often increased by dilution and perhaps by inhibition effects (3,5,7,9). This can prevent weakly positive specimen from being detected in group samples (3,8). Concerns about the sensitivity of group testing have been raised by French medical authorities, leading to a negative recommendation on their use in France(10).

Digital PCR (or RT-dPCR) is a PCR technique known for its higher sensitivity and precision over classical RT-PCR (11,12). Digital PCR has also been shown to be more resistant to PCR inhibitors (13). Recent studies have confirmed high sensitivity of RT-dPCR for the detection of SARS-CoV-2 (14–16).

In this study we propose a novel group testing protocol using a commercially available RT-dPCR assay and compare empirically the sensitivity of individual identification through RT-PCR with group testing by RT-dPCR for three groups sizes of 8, 16 and 32 samples. We find that, in our condition of evaluation, group testing by RT-dPCR has a better or similar sensitivity than the reference individual RT-PCR testing for groups of 8 and 16.

Material and Methods

Summary of the method of the comparative study

Overall, 448 patient samples are tested for SARS-CoV-2 by i) individual RT-PCR (local gold standard method), ii) RT-dPCR in 56 groups of 8 samples, iii) RT-dPCR in 28 groups of 16 samples and iv) RT-dPCR in 14 groups of 32 samples and results are compared between all four test protocols. In case of discordance between the results of individual RT-PCR testing and group testing in RT-dPCR, samples were re-analyzed individually by RT-dPCR, by the gold-standard RT-PCR and a confirmatory RT-PCR assay. The whole protocol is illustrated in Figure 1.




Figure 1 : Schematic of the structure of the comparative study.

Specimens collection, storage and pooling

Nasopharyngeal swabs of 448 patients screened for Covid-19 at the Bichat university hospital (Paris, France), one of the two Paris reference centers for emerging diseases, between May 6th and May 26th, 2020 were included. All samples were collected in universal transport medium (UTM) (Virocult® or eSwab™) and tested, within 15 hours maximum upon collection, for SARS-CoV-2 detection according to the local standards. Briefly, 400 µL of transport medium were tested by RT-PCR (Cobas SARS-CoV-2 test, Roche). All the remaining volume of transport medium of all specimens were kept at +5°C.

No later than 24 hours after routine screening, all samples with a leftover UTM volume above 600 µL were systematically included in the group testing analysis. Thus, 125 µL of each included specimen were sampled and randomly mixed with seven others to generate a total of 56 groups of 8 specimens with a final volume of 1 mL per group. Nucleic acids were extracted from each group prior to viral titration by RT-dPCR. The remaining volume of transport medium was stored at +5°C for further investigations if required.

According to the current French ethical laws, samples used in the current study were only included after the completion of all analysis required for the patient's care.

Detection of SARS-CoV-2 by routine individual RT-PCR testing

All 448 specimens were analyzed individually on a Cobas® 6800 system (Roche, Switzerland) for Covid-19 screening using the Cobas® SARS-CoV-2 Test kit targeting conserved regions for *ORF-1a/b* and *E*-gene. For each specimen, 400 µL of transport medium were mixed with 400 µL of Cobas® lysis buffer and loaded on the robot. During the run, extracts were eluted in 50 µL of which 27 µL were used in the RT-PCR amplification of *E* and *ORF-1a/b*. A sample was considered positive for routine screening of COVID-19 ("RT-PCR+") if either target had a Ct value below 40 PCR cycles.

Within 11 days maximum (and 20 days for "Sample_25659") upon storage at +5°C, some samples which had different results for RT-PCR and RT-dPCR were reassessed on the Cobas® 6800 system. To

compensate for the low remaining amounts of transport medium, the nasal swabs were vortexed once more into the remaining transport medium diluted 1 to 10 with new transport medium.

Extraction of total NAs on grouped samples

All nucleic acids extractions for RT-dPCR assays were performed on a MagNA Pure LC 2.0 (Roche, Switzerland) using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche, Switzerland) following manufacturer's instructions. For all sample groups, the total volume of 1 mL was used for the extraction. For individual samples, 200 µL was diluted with 800 µL of buffer before extraction. Nucleic acids were eluted from 1mL to 50 µL of the elution buffer provided with the kit and stored at +5°C for a maximum of 12 hours before analysis.

Preparation of groups of 16 and 32 individuals

After extraction of the 56 groups of 8 specimen (P8 extracts) and prior to viral titration by RT-dPCR, 28 groups of 16 individual samples (P16 groups) were obtained by mixing 15 µL of 2 P8 extracts and 14 groups of 32 (P32 groups) were obtained by mixing 10 µL of 2 P16 groups.

Detection of SARS-CoV-2 by grouped RT-dPCR testing

SARS-CoV-2 titration of the grouped samples by RT-dPCR was performed on the Naica system (Stilla Technologies, France) within the next three hours after extraction, using the COVID-19 Multiplex Digital PCR Detection Kit (Stilla Technologies, France/Apexbio, China). This one-step reverse-transcription PCR kit is a triplex PCR allowing amplification, detection and quantification of one sequence in the *N* gene, one sequence in the *ORF1ab* region of SARS-CoV2 and an endogenous internal control (IC) to assess the quality of the sample and extraction. These sequences are targeted by three TaqMan probes respectively labelled with a FAM, HEX and Cy[®]5 fluorophore.

As recommended by the kit manufacturer, the PCR mix for a single reaction contained 12.5 µL of dPCR MasterMix 1, 1 µL of dPCR Mix 2, 1 µL of COVID-19 Assay and 10.5 µL of either, P8, P16, P32, positive control, negative control or individual extract. The 25 µL of this PCR mix were loaded in the inlet ports of the Sapphire chips (Stilla Technologies, France). The chips were placed in the Naica Geode (Stilla Technologies, France) for droplets generation, reverse transcription and PCR amplification following the kit manufacturer's instructions.

After amplification, the chips were transferred to the Naica Prism3 (Stilla technologies, France) for fluorescence reading in the three detection channels and data were analyzed with Crystal Miner Software (Stilla Technologies, France) following the kit manufacturer's instructions.

An illustration of the resulting fluorescence dot-plots used to quantify the SARS-CoV-2 virus by RT-dPCR is shown in Supplementary Materials.

Individual confirmatory testing for SARS-CoV-2 by RT-PCR and RT-dPCR

In case of discrepancies between individual RT-qPCR and grouped RT-dPCR, RT-dPCR results were confirmed by extracting individually each sample of the group and retesting them individually according to the previously described RT-dPCR protocol. Confirmatory RT-qPCR test were also performed on individual samples as previously described with the Cobas SARS-CoV-2 assay and a third method, RealStar[®] SARS CoV-2 RT-PCR Kit (Altona Diagnostics, Germany), was also performed on an ABI 7500 thermocycler (ThermoFisher Scientific, United-States) from the same individual extraction as for the confirmatory RT-dPCR assay. Briefly, this latter assay targets all lineage B-betacoronaviruses by amplifying a sequence of the *E* gene and a sequence of the *S* gene specific to SARS-CoV-2 as well as a heterologous internal control. A sample was considered positive to SARS-CoV-2 if the Ct value of either target is below 40 PCR cycles.

LoB/LoD evaluation for SARS-CoV-2 detection using RT-dPCR

The Limit of Blank (LoB) and Limit of Detection (LoD) were evaluated for SARS-CoV-2 detection using the group testing approach used in the study on a cohort of 256 pre-epidemic nasal swab samples (negative control samples) that were collected between December 1st 2019 and January 31st 2020 and for which transport medium was stored at -20 °C within 48h after sampling.

Specimens were randomly grouped into 32 groups of 8 negative controls which were co-extracted and analyzed by RT-dPCR using the same protocol described above. The results for all 32 groups are given in Supplementary Materials. The LoB at 95% confidence level for the *N* target and the *ORF1ab* target is determined to be of 2 and 0 positive droplets respectively. The LoD at 95% confidence level for each target is of 0.49 copies / μ L (7 copies/PCR) and 0.24 copies/ μ L (3 copies/PCR), respectively.

Consequently, a threshold of a least 3 positive droplets in aggregate between both the *N* target and *ORF1ab* target is used to classify a sample as positive to SARS-CoV-2 by RT-dPCR in this study.

Results

Cohort description from routine RT-PCR testing

Using routine RT-PCR testing, 25 samples were identified as positive out of the 448 samples tested, corresponding to an average test positivity rate of 5.5%. The positivity rate decreased during the study period from 8.5% for the first 224 samples to 2.5% for the last 224 samples, in correlation with the decreasing disease prevalence observed during the month of May in France.

The average Ct value was of 30.0 and 27.3 for the *E* gene and *ORF* gene respectively, with minimum values of 16.5 and 16.3 and maximum values of 38.7 and >40 (not detected) (Figure 2).




Figure 2 : Distribution of Ct values for the *E* gene and *ORF* gene, as measured using individual reference RT-PCR with Cobas® 6800 SARS-CoV-2 assay, for the 25 positive samples.

Results from grouped RT-dPCR testing

All results for the detection of SARS-CoV-2 by RT-dPCR for the grouped extracts (P8) and the subsequent groups of 16 (P16) and 32 (P32) are presented in Table 1. Detailed results are listed in Supplementary Materials.

Number of RT-PCR positive sample(s) in the group	Results for P8 extracts			Results for P16 groups			Results for P32 groups		
	Total	dPCR -	dPCR +	Total	dPCR -	dPCR +	Total	dPCR -	dPCR +
0	35	32	3	12	11	1	2	2	0
1	18	1	17	10	2	8	6	0	6
2	2	0	2	4	0	4	3	0	3
3	1	0	1	1	0	1	1	0	1
4	0	0	0	1	0	1	1	0	1
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	1	0	1
Total	56	33	23	28	12	16	14	2	12

Table 1: Distribution of the samples identified as positive by the routine RT-PCR method (Cobas® SARS-CoV-2 assay) in the groups of 8, 16 and 32 and corresponding RT-dPCR detection of SARS-CoV-2 in the groups.

Because sample pooling was performed systematically as samples came in the laboratory for routing RT-PCR testing, the groups contain variable numbers of RT-PCR positive samples ("RT-PCR+" samples).

Given the positivity rate of RT-PCR at the time of the study, the majority of P8 extracts had no RT-PCR+ samples (35 out of 56) and 21 groups contained at least one RT-PCR+ sample, including 18 that had one single RT-PCR+ sample.

For the largest group size of 32 samples, only 2 P32 groups had no RT-PCR+ samples. 12 P32 groups had at least one RT-PCR+ sample, including 6 with only one single RT-PCR+ sample.

Detailed results for RT-dPCR in groups of 8

The results for SARS-CoV-2 detection by RT-dPCR in groups of 8 samples, detailed in Tables 1 and 2, are in concordance with the reference individual RT-PCR testing for 52 groups (corresponding for 416 samples), out of which 32 were RT-PCR negative groups and 20 groups contained at least one RT-PCR+ sample.

For the remaining 4 groups with discording results, three RT-PCR negative groups tested positive by RT-dPCR ("RT-PCR-/dPCR+" discordances – group IDs: P8_20, P8_28 and P8_39) and one RT-PCR+ group was found negative by RT-dPCR (RT-PCR+/dPCR- discordance – group ID: P8_02). The Ct values for the sample associated with the RT-PCR+/dPCR- discordance was of 34 and 32.3 for the *E* gene and *ORF1ab* with the Cobas® SARS-CoV-2 assay, respectively. This sample is referred to as *Sample 25659* for later discussion.

Complementary analysis of the discordances are depicted below.

Of note, out of the 8 individual samples with Ct > 35 for the *E* gene, 6 ended up to be the only positive sample in a P8 extract and all the corresponding groups were detected positive by RT-dPCR. The highest detected Ct values for the *E* gene and *ORF1ab* were 38.7 and >40 (not detected), respectively.

Confusion matrix for P8 extracts	Expected negatives (RT-PCR)	Expected positives (RT-PCR)	Total
Negatives in RT-dPCR	32	1	33
Positives in RT-dPCR	3	20	23
Total	35	21	56

Table 2: Confusion matrix for P8 extracts

Detailed results for RT-dPCR in groups of 16

The results for SARS-CoV-2 detection by RT-dPCR in groups of 16 samples, detailed in Tables 1 and 3, are in concordance with individual RT-PCR testing for 25 groups (corresponding for 400 samples), out of which 11 are RT-PCR- groups and 14 are RT-PCR+ groups. Among the three groups with discording results, one presented a RT-PCR-/dPCR+ discordance (Group ID: P16_14) and two RT-PCR+/dPCR- discordances (Group IDs: P16_13 and P16_28).

Of note, out of the 8 individual samples with Ct > 35 for the *E* gene, 5 ended up to be the only positive sample in a P16 group. Two of these groups are responsible for the 2 RT-PCR+/dPCR- discordances. The *E* gene and *ORF1ab* Ct values for these 2 samples were of [36.7; >40 (not detected)] and [36.3; 34.2], while the highest Ct values for a detected single positive sample were [38.3; >40 (not detected)].

Confusion matrix for P16 groups	Expected negatives (RT-PCR)	Expected positives (RT-PCR)	Total
Negatives in RT-dPCR	11	2	13
Positives in RT-dPCR	1	14	15
Total	12	16	28

Table 3: Confusion matrix for P16 groups

Detailed results for RT-dPCR in groups of 32

The results for SARS-CoV-2 detection by RT-dPCR in groups of 32 are in concordance with individual RT-PCR testing for all 14 groups (corresponding for 448 samples) and are depicted in Tables 1 and 4.

Out of the 8 individual samples with Ct >35 for the *E* gene, 3 ended up to be the only positive sample in a P32 group. All such 3 P32 groups tested positive by RT-dPCR. The highest detected Ct values for the *E* gene and *ORF1ab* is of [36.7; >40 (not detected)].

Confusion matrix for P32 groups	Expected negatives (RT-PCR)	Expected positives (RT-PCR)	Total
Negatives in RT-dPCR	2	0	2
Positives in RT-dPCR	0	12	12
Total	2	12	14

Table 4: Confusion matrix for P32 groups

Investigation of RT-PCR-/dPCR+ discordances

As detailed above, three P8 extracts (P8_20, P8_28 & P8_39) and one P16 group (P16_14) tested positive by RT-dPCR while containing only RT-PCR negative samples. P16_14 originates from a combination of groups with opposite discordances: P8_27 (RT-PCR+/dPCR-) and P8_28 (RT-PCR-/dPCR+) groups.

To further investigate these RT-PCR-/dPCR+ discordances, confirmatory testing RT-dPCR was performed on all individual samples from corresponding groups. For each group, one sample tested positive by individual RT-dPCR, with measured concentrations of viral RNA ranging from 128 copies per reaction to 2 copies per reaction for the *N* gene, and from 106 to 1 copies for the *ORF1ab* gene. The three corresponding dPCR+ samples (sample IDs: 52042, 56075 and 60401) were retested on the Cobas® 6800 system and by confirmatory individual RT-qPCR using the Altona assay. All results are given in the Supplementary Materials.

Two samples were found positive using the Altona assay with Ct values ranging between 28.4 and 33 for the *E* and *S* genes. Among them, the sample presenting the highest viral load by RT-dPCR (Sample 56075) was also found positive by the Cobas® confirmatory assay with a high Ct value of 36.7 for the *E* gene while the *ORF* gene was not detected. The remaining sample tested negative with both the confirmatory Cobas assay and the Altona assay. It had borderline levels of positive droplets in RT-dPCR (*N*=2; *ORF1ab*=1).

Based on these results and for further sensitivity discussions, samples 52042 and 56075 that tested positive by both RT-dPCR and Altona RT-PCR are considered as true positive samples. Sample 60401 is considered an RT-dPCR false positive pending further analysis.

Investigation of the sample RT-PCR+/dPCR-

One group of 8 (P8_02) was tested negative by RT-dPCR and contained one RT-PCR+ sample (*Sample 25659*) with Ct values of 34 and 32.3 for the *E* gene and *ORF1ab* respectively. *Sample 25659* was subsequently retested by RT-PCR on the Cobas protocol and was also re-extracted individually and retested by individual RT-dPCR.

Sample_25659 was found to be borderline negative by RT-dPCR (N=2; ORF1ab=0) but Ct values of 37.3 and 34.9 were found for *E* and *ORF* respectively in the second Cobas® assessment.

Based on these results and for further sensitivity discussions, sample 25659 is considered as a true positive samples.

Correlation between RT-dPCR measurements and Ct values

A good correlation was observed between the number of positive droplets observed in RT-dPCR and the Ct values of the positive samples contained in the groups. See Supplementary Materials for more details.

Discussion

In this work, we assessed the sensitivity and specificity of group testing combined with digital PCR for SARS-CoV-2 detection. Three different group sizes were investigated using a commercially available digital PCR assay, the COVID-19 Multiplex Digital PCR Detection Kit (Stilla Technologies, France/Apexbio, China). This assay demonstrated a low LoB (at 2 and 0 positive droplets per PCR for *N* and *ORF1ab* genes, respectively) and low LoD (at 5 and 3 copies/PCR for *N* and *ORF1ab* genes, respectively). This LoD is lower than most estimation for WHO and other reference RT-PCR assays typically ranging between 5 to 500 copies/PCR (17,18).

For our analysis, we proposed a protocol of group screening performed by RT-dPCR with secondary individual re-testing of positive groups as illustrated in Figure 3.




Figure 3 : Graph of the suggested practical protocol for implementation of group testing by RT-dPCR.

We assessed this protocol by assessing in real-life condition 448 consecutive samples grouped by 8, 16 and 32 samples.

We observed a better sensitivity than individual RT-PCR testing for groups of 8 samples. Indeed, a total of 23 groups of 8 samples tested positive and included 26 true positive samples. Only 25 samples were identified as positive using reference individual RT-PCR testing, corresponding to an +4% improvement

in sensitivity. Two among the three samples associated with RT-PCR-/dPCR+ discordances were confirmed as true positive by RT-PCR using a SARS-CoV-2 specific assay from Altona. The last one was not confirmed as positive by RT-PCR and is undergoing further investigations. One sample was associated to a RT-PCR+/dPCR- discrepant results and is also considered a true positive sample as confirmed by RT-PCR retesting. Further investigation by sequencing is underway on these 4 samples in an effort to rigorously assess the existence and nature of nucleic acids variations responsible for the discording results.

Grouped testing by RT-dPCR has similar sensitivity to individual RT-PCR testing for a group size of 16 samples. 15 groups of 16 samples tested by RT-dPCR positive and included a total of 25 true positive samples, of which 23 are RT-PCR positive samples and 2 are RT-PCR-/dPCR+ samples. However, 2 RT-PCR+ groups tested negative with grouped RT-dPCR. This is likely explained by high Ct values of the single positive sample included in each of these 2 groups.

Testing in the 14 groups of 32 samples by RT-dPCR has 100% concordance with the reference RT-PCR testing. Re-testing positive groups by RT-dPCR would have likely led to better sensitivity than RT-PCR. However, we are careful in drawing conclusions for groups of 32 given the limited data points in this case as only 14 groups, including only 2 RT-PCR negative groups.

An alternative and even more cost-effective group testing protocol could be to perform the re-testing steps using RT-PCR with Cobas or Altona assays. In these protocols, the sensitivity becomes dependent on the RT-PCR kit used, leading to potential discrepancies with RT-dPCR as observed in our results for groups of 8 samples. However, our data suggest that performing the individual tests for groups of 8 and 16 with a RT-PCR assay would still have a similar sensitivity.

Overall, our data indicates that COVID-19 group testing combined with digital PCR for large group sizes of 8 and 16 samples, followed by individual re-testing of positive groups, has better or similar sensitivity than individual RT-PCR testing. Groups of 32 samples could also be considered, but our analysis needs to be confirmed in the future as, due to the epidemiological situation at the time, a low number of negative groups and groups containing a single positive sample were assessed.

The gain in sensitivity of the proposed method is likely due to a combination of *i)* a concentration effect due to performing the pooling prior extraction and performing the extraction step from a large volume of 1 mL of pooled transport medium and *ii)* the intrinsic superior sensitivity of digital PCR compared to RT-PCR, as demonstrated previously for SARS-CoV-2 (14–16) and other viruses (12,19) detection.

Below standard sensitivity is one of the main reasons why group testing has not been widely adopted for COVID-19 testing, whilst research groups have advocated for its implementation as a solution to the world-wide un-met demand for tests and reagent shortage(2-9).

The current study suggests that the high sensitivity of group testing could be achieved using by digital PCR instead of RT-PCR in the first group screening step. It makes the approach viable for large-scale, low cost patient screening with minimum reagent consumption. For a test positivity rate of 1%, our group testing protocol would save 79%, 80% and 69% of reagents compared to individual testing, for group sizes of 8, 16 and 32 samples. Group size does not significantly impact cost or reagent consumption for group sizes above 8 samples and test positivity rates below 1%. Consequently, the choice of group size (8, 16 or 32) is mostly a balance of sensitivity and test capacity. Our results indicate that group testing by digital PCR and a group size of 16 would increase testing capabilities by more than 10-fold while having a sensitivity comparable to the current standard of individual testing by RT-PCR.

Group testing can be used in various context where testing is not currently put in place due to testing capacity or with strong economics constraints and where SARS-CoV-2 prevalence is low. In countries where the pandemic is not yet under control or could re-emerge, enhancing testing capacity is essential to winning the battle against COVID-19. In countries where the first wave is fading, the fight against COVID-19 goes through a combination between a test / trace / isolate strategy and social distancing. Increasing the range of people tested amongst contacts with positive cases, but also periodic testing of population in frequent contact with others (e.g. nurses, transportation workers, clerks, etc...) as well as in fragile populations such as nursing homes can be part of a strategy against COVID-19 while allowing a relaxation of social distancing measures at the same time. Group testing can help in all of these situations.

References

1. Dorfman R. The Detection of Defective Members of Large Populations. *The Annals of Mathematical Statistics*. 1943;14(4):436-40.
2. Gollier C, Gossner O. Group Testing against COVID-19 [Internet]. Working Papers. Center for Research in Economics and Statistics; 2020 avr [cité 1 juin 2020]. (Working Papers). Report No.: 2020-04. Disponible sur: <https://ideas.repec.org/p/crs/wpaper/2020-04.html>
3. Yelin I, Aharoni N, Shaer Tamar E, Argoetti A, Messer E, Berenbaum D, et al. Evaluation of COVID-19 RT-qPCR test in multi-sample pools. *Clinical Infectious Diseases*. 2 mai 2020;ciaa531.
4. Schmidt M, Hoehl S, Berger A, Zeichhardt H, Hourfar K, Ciesek S, et al. FACT- Frankfurt adjusted COVID-19 testing- a novel method enables high-throughput SARS-CoV-2 screening without loss of sensitivity. *medRxiv*. 1 mai 2020;2020.04.28.20074187.
5. Anderson C, Castillo F, Koenig M, Managbanag J. Pooling nasopharyngeal swab specimens to increase testing capacity for SARS-CoV-2. *bioRxiv*. 22 mai 2020;2020.05.22.110932.
6. Hogan CA, Sahoo MK, Pinsky BA. Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2. *JAMA*. 19 mai 2020;323(19):1967.
7. Abdalhamid B, Bilder CR, McCutchen EL, Hinrichs SH, Koepsell SA, Iwen PC. Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources. *American Journal of Clinical Pathology*. 5 mai 2020;153(6):715-8.
8. Griesemer SB, Van Slyke G, St. George K. Assessment of sample pooling for clinical SARS-CoV-2 testing [Internet]. *Microbiology*; 2020 mai [cité 1 juin 2020]. Disponible sur: <http://biorxiv.org/lookup/doi/10.1101/2020.05.26.118133>
9. Lohse S, Pfuhl T, Berkó-Göttel B, Rissland J, Geißler T, Gärtner B, et al. Pooling of samples for testing for SARS-CoV-2 in asymptomatic people. *The Lancet Infectious Diseases*. avr 2020;S1473309920303625.
10. HCSP. Coronavirus SARS-CoV-2 : poolage des tests RT-PCR [Internet]. Rapport de l'HCSP. Paris: Haut Conseil de la Santé Publique; 2020 mai [cité 1 juin 2020]. Disponible sur: <https://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=828>
11. Strain MC, Lada SM, Luong T, Rought SE, Gianella S, Terry VH, et al. Highly Precise Measurement of HIV DNA by Droplet Digital PCR. Wu Y, éditeur. *PLoS ONE*. 3 avr 2013;8(4):e55943.

12. Huang J-T, Liu Y-J, Wang J, Xu Z-G, Yang Y, Shen F, et al. Next Generation Digital PCR Measurement of Hepatitis B Virus Copy Number in Formalin-Fixed Paraffin-Embedded Hepatocellular Carcinoma Tissue. *Clinical Chemistry*. 1 janv 2015;61(1):290-6.
13. Dingle TC, Sedlak RH, Cook L, Jerome KR. Tolerance of Droplet-Digital PCR vs Real-Time Quantitative PCR to Inhibitory Substances. *Clinical Chemistry*. 1 nov 2013;59(11):1670-2.
14. Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, et al. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. *Clinical Infectious Diseases*. 28 mars 2020;ciaa345.
15. Dong L, Zhou J, Niu C, Wang Q, Pan Y, Sheng S, et al. Highly accurate and sensitive diagnostic detection of SARS-CoV-2 by digital PCR [Internet]. *Public and Global Health*; 2020 mars [cité 1 juin 2020]. Disponible sur: <http://medrxiv.org/lookup/doi/10.1101/2020.03.14.20036129>
16. Suo T, Liu X, Feng J, Guo M, Hu W, Guo D, et al. ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens. *Emerging Microbes & Infections*. 22 mai 2020;1-30.
17. Visseaux B. Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the first rapid multiplex PCR commercial assay for SARS-CoV-2 detection. *Journal of Clinical Microbiology*.
18. Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, et al. Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR assays [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2020 avr [cité 20 avr 2020]. Disponible sur: <http://medrxiv.org/lookup/doi/10.1101/2020.03.30.20048108>
19. Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppas D, Salgado M, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. *Nature*. avr 2019;568(7751):244-8.

Supplementary Materials

S1 – Data format for RT-dPCR as obtained with the Naica System




Figure S1.1: Fluorescence results as displayed in the Crystal Miner software showing 1D dot-plots of a positive (P8_42) and a negative (P8_44) pool of 8 samples in the FAM (A), HEX (B) and Cy5 (C) channels. The horizontal line marks the threshold above which droplets (represented as dots) are considered positive for the amplification of N, ORF1ab and for the endogenous internal control respectively. The thresholds are set by manufacturer at 20 000 RFUs, 15 000 RFUs and 15 000 RFUs for the FAM, HEX and Cy5 channels. (D) 3D dot-plots of P8_42: if the concentration of either target is high enough, co-encapsulation of several targets can occur in a droplet leading to the apparition of clusters for double positive droplets (cyan, yellow and purple) and triple positive droplets (light grey). Triple negative droplets, containing no target, are shown in the dark grey cluster.




Figure S1.2: Image of the droplet crystal obtained using the Naica System on grouped extracts P8_22, including a zoom on a sub-region of the crystal. Droplet color code: dark grey = negative for all targets ; bleu : positive for N gene only ; green : positive for ORF1ab only ; red : positive for IC only ; cyan : positive for N and ORF1ab genes ; magenta: positive for N gene and IC ; yellow: positive for ORF1ab gene and IC ; white / mixed: positive for all. The droplet crystal contains 25 820 analyzable droplets, out of which 1 057, 883 and 21 121 were positive for the N, ORF1ab and IC respectively.

S2 – Result table for LoB & LoD calculations

Sample ID	Number of droplets	Pos. droplets (N+ORF1ab)	Pos. droplets (N)	Pos. droplets (ORF1ab)	IC (cp/μL)
Group 1	19460	0	0	0	31430
Group 2	20641	0	0	0	10985
Group 3	21449	0	0	0	4054
Group 4	20983	0	0	0	15143
Group 5	19881	1	1	0	7401
Group 6	20609	0	0	0	8783
Group 7	19044	0	0	0	6249
Group 8	20787	0	0	0	8759
Group 9	21470	0	0	0	10271
Group 10	18952	0	0	0	17578
Group 11	23424	0	0	0	8222
Group 12	22748	0	0	0	9875
Group 13	23747	0	0	0	10275
Group 14	24886	0	0	0	4266
Group 15	24079	0	0	0	10264
Group 16	24718	0	0	0	13219
Group 17	24228	0	0	0	10186
Group 18	23742	0	0	0	8431
Group 19	23880	0	0	0	7628
Group 20	23613	0	0	0	3111
Group 21	25723	0	0	0	8987
Group 22	25522	0	0	0	7411
Group 23	24781	0	0	0	6894
Group 24	7074	0	0	0	5884
Group 25	27003	0	0	0	8911
Group 26	27138	0	0	0	5552
Group 27	24425	0	0	0	7886
Group 28	27017	0	0	0	7484
Group 29	26722	0	0	0	9963
Group 30	26088	0	0	0	2492
Group 31	26747	0	0	0	5703
Group 32	26728	0	0	0	5825

Table S2: Detection results in number of positive droplets for *N*, *ORF1ab*, *N+ORF1ab* and IC by RT-dPCR in 32 groups of 8 pre-epidemic samples.

The pre-epidemic groups were used as negative controls for SARS-CoV-2 detection. Only one out of 32 (group 5) had one positive droplet for the *N* target out of 19881 droplets analyzed. The LOB at 95% confidence level for this RT-dPCR assay was estimated automatically by the Gene-Pi online statistical tool (<https://www.gene-pi.com/statistical-tools/loblod/>), considering a droplet volume of 0.548 nL as specified by the manufacturer. The LOD at 95% confidence level is computed from the experimental LOB. The LOB for the *N* and *ORF1ab* targets are found to be of 2 and 0 droplets respectively. The LODs are found to be of 0.46 copies/μL and 0.22 copies/μL, or equivalently of 7 and 3 copies per PCR reaction.

Using a joint analysis, a LOB analysis can be performed for the combination of the *N* and *ORF1ab* targets. In the case, the sum of the positives for the *N* and *ORF1ab* target is used as the measure and the LOB for the sum is 2 positive droplets. Consequently, in this study, a RT-dPCR result is considered as positive when the sum of positive droplets in the *N* and *ORF1ab* targets is of 3 droplets or more (strictly greater than 2).

For details on calculation models, see:

- https://www.gene-pi.com/wp-content/uploads/2018/03/Memo_LOB_calculation_method.pdf
- https://www.gene-pi.com/wp-content/uploads/2019/11/GenePi_Memo_LOD_calculation_method-1.pdf

S3 - Full results of pooled testing by RT-dPCR

Sample_ID	Ct_E	Ct_ORF	P8_##	# of droplets	Pos droplets N	Pos droplets ORF	IC [C] (cp/μL)	COBAS/dPCR status	P16_##	# of droplets	Pos droplets N	Pos droplets ORF	IC [C] (cp/μL)	COBAS/dPCR status	P32_##	# of droplets	Pos droplets N	Pos droplets ORF	IC [C] (cp/μL)	COBAS/dPCR status
25652	21.2	20.9	P8_01	25340	25340	25128	15556	+/+	P16_01	25262	25196	22657	9080	+/+	P32_01	17348	16047	11332	9237	+/+
25653	38.01	0																		
+ 6 COBAS negative samples																				
25659	34.02	32.26	P8_02	25685	0	0	3642	+/-												
+ 7 COBAS negative samples																				
8 COBAS negative samples			P8_03	22995	1	0	5530	-/-	P16_02	24508	0	0	10026	-/-						
8 COBAS negative samples			P8_04	26245	0	0	14896	-/-												
27241	34	32.1	P8_05	26634	63	42	24859	+/+	P16_03	26718	980	350	15988	+/+	P32_02	4298	3890	3693	17412	+/+
+ 7 COBAS negative samples																				
27304	28.8	28.12	P8_06	27184	1767	650	8160	+/+												
+ 7 COBAS negative samples																				
27316	27.71	27.1	P8_07	25752	3597	2667	13527	+/+	P16_04	26735	26497	26315	19941	+/+						
+ 7 COBAS negative samples																				
27342	26.27	25.24	P8_08	26060	26059	26056	28478	+/+												
+ 7 COBAS negative samples																				
30923	38.27	ND	P8_09	25655	4	1	16784	+/+	P16_05	26446	4	1	18236	+/+	P32_03	21285	83	54	19589	+/+
+ 7 COBAS negative samples																				
8 COBAS negative samples			P8_10	25511	0	0	19934	-/-												
8 COBAS negative samples			P8_11	22083	0	0	17689	-/-	P16_06	27274	224	125	21805	+/+						
25736	34.5	32	P8_12	22503	418	256	29721	+/+												
+ 7 COBAS negative samples																				
31173	38.73	ND	P8_13	22408	3	2	13871	+/+	P16_07	23420	23420	23418	13459	+/+	P32_04	24222	24222	24221	14252	+/+
+ 7 COBAS negative samples																				
31271	18.71	17.81	P8_14	22982	22982	22974	14204	+/+												
31278	36.52	34.83																		
31417	25.04	24.61																		
+ 5 COBAS negative samples																				
8 COBAS negative samples			P8_15	22883	0	0	17210	-/-	P16_08	21923	17166	14218	14676	+/+						
31397	21.6	21.16	P8_16	24406	23431	21878	12568	+/+												
31415	25.04	24.61																		
+ 6 COBAS negative samples																				
8 COBAS negative samples			P8_17	25825	0	0	13476	-/-	P16_09	24573	739	554	13055	+/+	P32_05	23569	319	202	12648	+/+
51318	28.35	27.89	P8_18	25304	1543	1189	15304	+/+												
+ 7 COBAS negative samples																				
51958	35.15	32.25	P8_19	25088	40	39	16078	+/+	P16_10	26314	32	25	16918	+/+						
+ 7 COBAS negative samples																				
52042	ND	ND	P8_20	25083	5	2	14024	-/+												
+ 7 COBAS negative samples																				
8 COBAS negative samples			P8_21	24808	0	2	18935	-/-	P16_11	24624	468	360	12282	+/+	P32_06	26550	305	212	13244	+/+
52408	28.81	28.22	P8_22	25820	1057	883	7399	+/+												
+ 7 COBAS negative samples																				
8 COBAS negative samples			P8_23	23991	0	0	12420	-/-	P16_12	25837	0	0	14885	-/-						
8 COBAS negative samples			P8_24	25510	0	0	16601	-/-												

Sample_ID	Ct_E	Ct_ORF	P8_#	# of droplets	Pos droplets N	Pos droplets ORF	IC [C] (cp/μL)	COBAS/dPCR status	P16_#	# of droplets	Pos droplets N	Pos droplets ORF	IC [C] (cp/μL)	COBAS/dPCR status	P32_#	# of droplets	Pos droplets N	Pos droplets ORF	IC [C] (cp/μL)	COBAS/dPCR status
8 COBAS negative samples			P8_25	25585	1	0	13405	-/-	P16_13	25257	0	0	15031	+/-	P32_07	25105	7	2	13330	+/+
27309	36.65	ND	P8_26	25498	5	1	18210	+/-												
+ 7 COBAS negative samples																				
8 COBAS negative samples			P8_27	25770	0	0	14721	-/-	P16_14	25364	13	5	13146	-/+						
56075	ND	ND	P8_28	25667	32	19	16170	-/+												
+ 7 COBAS negative samples																				
8 COBAS negative samples			P8_29	25568	0	0	11813	-/-	P16_15	27217	0	0	12192	-/-	P32_08	26284	0	0	11980	-/-
8 COBAS negative samples			P8_30	25757	0	0	12565	-/-												
8 COBAS negative samples			P8_31	25476	0	0	8230	-/-	P16_16	27198	0	0	12741	-/-						
8 COBAS negative samples			P8_32	25324	0	0	17214	-/-												
8 COBAS negative samples			P8_33	25765	1	0	17060	-/-	P16_17	26670	0	0	17539	-/-	P32_09	26986	4628	3336	13335	+/+
8 COBAS negative samples			P8_34	25803	0	0	17915	-/-												
59120	24.1	23.28	P8_35	26095	14584	11406	9821	+/+	P16_18	25884	8381	6405	11333	+/+						
+ 7 COBAS negative samples																				
8 COBAS negative samples			P8_36	25774	0	0	13463	-/-												
8 COBAS negative samples			P8_37	24635	1	0	10338	-/-	P16_19	26555	0	0	14937	-/-	P32_10	25842	230	184	12290	+/+
8 COBAS negative samples			P8_38	24082	1	0	17996	-/-												
60401	ND	ND	P8_39	26374	1	3	15263	-/+	P16_20	27345	506	415	11245	+/+						
+ 7 COBAS negative samples																				
60611	28.14	27.86	P8_40	26259	979	757	7136	+/+												
+ 7 COBAS negative samples																				
74465	16.5	16.3	P8_41	26883	26883	26883	8581	+/+	P16_21	24825	24825	24825	9690	+/+	P32_11	26391	26391	26391	9388	+/+
+ 7 COBAS negative samples																				
75547	31.3	29.4	P8_42	27389	2045	1905	11346	+/+												
+ 7 COBAS negative samples																				
8 COBAS negative samples			P8_43	26105	0	0	5791	-/-	P16_22	26078	0	0	9354	-/-						
8 COBAS negative samples			P8_44	25839	0	0	14504	-/-												
8 COBAS negative samples			P8_45	27194	0	1	12374	-/-	P16_23	25239	0	0	17469	-/-	P32_12	26536	0	0	18153	-/-
8 COBAS negative samples			P8_46	26285	0	0	22379	-/-												
8 COBAS negative samples			P8_47	25420	0	0	24184	-/-	P16_24	26470	0	0	19399	-/-						
8 COBAS negative samples			P8_48	26010	0	0	14457	-/-												
8 COBAS negative samples			P8_49	24858	0	0	12808	-/-	P16_25	25065	4	3	13301	+/+	P32_13	26706	2	6	12266	+/+
79484	35.73	34.45	P8_50	25900	7	7	13425	+/+												
+ 7 COBAS negative samples																				
8 COBAS negative samples			P8_51	24696	0	0	16954	-/-	P16_26	25356	0	0	11840	-/-						
8 COBAS negative samples			P8_52	25416	0	0	4837	-/-												
8 COBAS negative samples			P8_53	25625	0	0	12554	-/-	P16_27	22665	0	0	9484	-/-	P32_14	26044	2	1	6664	+/+
8 COBAS negative samples			P8_54	23544	0	0	6078	-/-												
83938	36.3	34.2	P8_55	22501	5	3	2607	+/+	P16_28	20171	2	0	5581	+/-						
+ 7 COBAS negative samples																				
8 COBAS negative samples			P8_56	23211	0	0	7245	-/-												

Table S3: Results for A) individual reference RT-PCR testing; B) grouped testing by RT-dPCR for P8 extracts; C) grouped testing by RT-dPCR for P16 groups; and D) grouped testing by RT-dPCR for P32 groups. Highlighted in light green: results are in concordance (-/- or +/+). Highlighted in light orange: COBAS+/dPCR- discordance. Highlighted in light red: COBAS-/dPCR+ discordance. ND= "Not detected".

S4 – Detailed results of confirmatory testing for COBAS-/dPCR+ discordances

Sample ID	COBAS reference	P8 extract number	dPCR+/dPCR-	N cp / rnx	ORF1ab cp / rnx	IC cp / rnx	Altona E gene	Altona S gene	COBAS N	COBAS OFR
51996	COBAS-	20	dPCR-	1	0	7 502	NT	NT	NT	NT
52019	COBAS-	20	dPCR-	0	0	25 944	NT	NT	NT	NT
52031	COBAS-	20	dPCR-	0	0	68 983	NT	NT	NT	NT
52035	COBAS-	20	dPCR-	0	0	28 215	NT	NT	NT	NT
52042	COBAS-	20	dPCR+	16	19	a89 747	33	31.9	ND	ND
52047	COBAS-	20	dPCR-	0	0	122 825	NT	NT	NT	NT
52060	COBAS-	20	dPCR-	0	0	17 237	NT	NT	NT	NT
52062	COBAS-	20	dPCR-	0	0	105 711	NT	NT	NT	NT
56075	COBAS-	28	dPCR+	128	106	69 268	29	28.4	36.7	ND
56077	COBAS-	28	dPCR-	0	0	34 656	NT	NT	NT	NT
56083	COBAS-	28	dPCR-	0	0	71 410	NT	NT	NT	NT
56191	COBAS-	28	dPCR-	0	0	22 471	NT	NT	NT	NT
56211	COBAS-	28	dPCR-	0	0	21 185	NT	NT	NT	NT
56275	COBAS-	28	dPCR-	0	0	22 771	NT	NT	NT	NT
56303	COBAS-	28	dPCR-	0	0	56 797	NT	NT	NT	NT
56307	COBAS-	28	dPCR-	0	0	59 159	NT	NT	NT	NT
60241	COBAS-	39	dPCR-	0	0	46 988	NT	NT	NT	NT
60281	COBAS-	39	dPCR-	1	0	73 581	NT	NT	NT	NT
60310	COBAS-	39	dPCR-	0	0	11 420	NT	NT	NT	NT
60334	COBAS-	39	dPCR-	0	0	32 663	NT	NT	NT	NT
60345	COBAS-	39	dPCR-	0	0	81 004	NT	NT	NT	NT
60362	COBAS-	39	dPCR-	0	0	36 943	NT	NT	NT	NT
60389	COBAS-	39	dPCR-	0	0	825	NT	NT	NT	NT
60401	COBAS-	39	dPCR+	2	1	43 651	ND	ND	ND	ND

Table S4: Results of the individual reassessment by both RT-dPCR and RT-PCR (Altona and Cobas®) for the samples from the 3 “COBAS-/dPCR+” discordant groups. NT = “Not tested”. ND = “Not detected”.

S5 - Absence of discordance in groups of 32

In this study, we did not observe any discordance for test results in groups of 32 when compared to the reference individual RT-PCR results. In particular and surprisingly, there were no qPCR+/dPCR- discordances although we would suspect an increased occurrence of such discordances as group size increases from the dilution effect of group testing.

Interestingly, the 2 samples that were associated with the 2 qPCR+/dPCR- discordances for groups of 16 (with Ct values of [36.7; ND] and [36.3; 34.2] respectively) are both P32 groups that contained one single positive qPCR+ sample. Consequently, these two samples were successfully detected by RT-dPCR in groups of 32 (P32_07 & P32_14) but not detected in the groups of 16 (P16_13 & P16_28).

In case of P32_07, the group of 32 is a combination of 2 P16 groups with opposite discordances: P16_13 (qPCR+/dPCR-) and P16_14 (qPCR-/dPCR+). It is likely that the RNA templates from the P16_14 group are those that were detected in the P32_07 group.

In the case of P32_14, the number of positive droplets observed in RT-dPCR is right above the threshold of 3 positive droplets (N=2; ORF1ab=1) while for the corresponding group of 16 (P16_28), the number of positive droplets is just below with 2 droplets (N=2; ORF1ab=0). In this case, statistical variations due to sampling error could explain the observation.

S6 – Correlation between RT-dPCR measurements and Ct values




Figure S6.1: Plot of the number of positive droplets measured by RT-dPCR for the N gene target in the groups of 8, 16 and 32 versus the predicted equivalent Ct value of the E gene of an RT-PCR measurement of the group using the Cobas® SARS-CoV-2 assay. The predicted equivalent Ct value of a group is defined as an average of the Ct values of the positive samples included in the group, taking into account the logarithmic scale of the Ct value.




Figure S6.2: Plot of the number of positive droplets measured by RT-dPCR for the ORF1ab gene target in the groups of 8, 16 and 32 versus the predicted equivalent Ct value of the OFR gene of an RT-PCR measurement of the group using the Cobas® SARS-CoV-2 assay. The predicted equivalent Ct value of a group is defined as an average of the Ct values of the positive samples included in the group, taking into account the logarithmic scale of the Ct value.